Multifocal papillary thyroid carcinoma (mPTC) comprises about 20-30% of PTC. In mPTC, individual tumor foci can be identical or frequently composed of different histological types including follicular, solid, tall-cell or conventional patterns. We report a case of mPTC consisting of one encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) and three conventional PTCs in a 44-year-old woman. This case genetically demonstrates unique features including the simultaneous presence of the BRAF V600E (T1799A) mutation and the BRAF K601E (A1801G) mutation in conventional PTC and FVPTC, respectively.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. There are several histopathological variants other than the conventional type, and among these variants the follicular variant (FVPTC) is the most common. 1 Although FVPTC has been recognized for more than 50 years, its diag nostic features, molecular mechanisms involved and patient prognosis remain unclear. 1 FVPTC has a wide range of observer variation in diagnosis and its actual proportion in PTC varies depending on the study.
The BRAF V600E mutation has been established as a reli able genetic marker of PTC with a prevalence of 45% to 91.1% of all conventional PTCs. 2, 3 However, this mutation is absent or less commonly detected in FVPTC. FVPTC is characterized and identified by another distinct BRAF mutation, K601E, which has been detected with a relatively low frequency of 7%. 4 In addition to these differences in BRAF mutations, FVPTC also exhibits different genetic alterations, which include increas ed rates of allelic imbalance and aneuploidy as compared to con ventional PTCs. 57 Multifocal PTCs (mPTCs) are found in about 20% to 30% of all PTCs according to previously published reports. 8 In mPTC, individual tumor foci can be identical or frequently composed of different histological types including follicular, solid, tallcell or conventional patterns. These mPTC foci may occur from in traglandular metastases from a single dominant tumor, or arise independently as unrelated neoplastic clones from a distinct progenitor cell. 9, 10 There have been several previous studies about the origin of mPTC foci with evidence supporting both argu ments, i.e., de novo carcinogenesis or intrathyroidal metastasis. By determining the presence of a polymorphism in the Xlinked androgenreceptor gene or heterogeneous distribution of BRAF mutations among noncontiguous, discrete tumor foci of mPTC, some researchers have previously suggested that mPTC often arises independently. 9, 10 In contrast, Jovanovic et al. 11 recently showed that the majority of mPTCs demonstrate the features of monoclonal derivation in spite of morphological diversity of each tumor foci in analysis based on allelic imbalances and the BRAF V600E mutation, suggesting intrathyroidal spread from a primary tumor. In another recent report by Jovanovic et al., 5 FVPTC foci of mPTCs had different patterns of loss of hetero zygocity and BRAF V600E from other foci in spite of mono clonality and this was similar to the abovementioned results comparing solitary FVPTC and other PTCs. The complexity of arguments about the origin of mPTC suggests that mPTC may arise through diverse and heterogeneous genetic mechanisms.
Here, we describe a genetically unique case of mPTC consist ing of one encapsulated follicular variant harboring the BRAF K601E mutation and three conventional types harboring the BRAF V600E mutation.
CASE REPORT
A 44yearold female was referred from a local clinic for a papillary carcinoma of the thyroid that was diagnosed by fine needle aspiration. The patient did not have a past history of neck radiation or a family history of thyroid cancer. Thyroid ul trasonography revealed a spiculated, hypoechoic solid nodule measuring 0.8 cm in diameter with a capsular invasion at the left paraisthmic area of the thyroid. The ultrasonography also revealed three smooth, oval, and slightly hypoechoic solid nod ules measuring 2.3 cm, 1.3 cm, and 0.8 cm in diameter at the right upper, middle, and lower lobes, respectively. The lymph nodes at the central and lateral neck were not significantly en larged. Total thyroidectomy with central node dissection was performed.
Gross findings
The specimen consisted of a reddish brown total thyroidecto my tissue. The right thyroid gland measured 4.5×2.3×2.0 cm, and the left thyroid gland measured 4.5×2.3×1.7 cm. Both glands weighed 20 g in total. On the serial cut sections of the right thyroid, there were two illdefined grayish white solid masses measuring 1.2×0.9×0.6 cm and 2.1×1.9×1.5 cm at the upper and lower poles, respectively. At the right mid pole, there also was a welldefined tan, yellow, solid mass measuring 1.3×1.1×0.8 cm. On the serial cut sections of the left lobe, there was an illdefined grayish white nodule measuring 0.8× 0.6×0.5 cm at the paraisthmic area.
Microscopic findings
Histological examination revealed three conventional PTCs in the right upper and lower poles and also in the left paraisth mic area. All the conventional PTCs revealed an infiltrative growth pattern with typical histological features. The mass at the right mid pole was characterized by total encapsulation without papilla formation or psammoma bodies and correspon ded to the encapsulated variant of FVPTC. Characteristic nu clear features, particularly nuclear enlargement, chromatin clear ing and irregular nuclear contours were present. Nuclear grooves were present, but not frequently. Deeply eosinophilic colloid with peripheral scalloping was also present (Fig. 1) . Three peri thyroidal lymph nodes were involved by conventional PTC.
Immunohistochemical findings
Immunohistochemical staining was performed on the 5µm thick sectioned slides obtained from the formalinfixed, paraffin embedded tissue using an autoimmunostainer (Ventana, Tucson, AZ, USA) with monoclonal mouse anticytokeratin 19 (CK19) antibody (clone A53B/A2.26, NeoMarkers, Fremont, CA, USA) and polyclonal rabbit antigalectin3 antibody (Zymed, San Francisco, CA, USA). The tumor cells of the conventional PTC exhibited a strong, diffusely positive immunoreactivity to CK19 (1:1,500) and galectin 3 (1:100), whereas the tumor cells of the follicular variant revealed no reactivity to galectin 3, and showed only focal and weak staining to CK19 (Fig. 2 ).
Molecular analysis
The tumor cells were microdissected from both the conven tional and follicular variant areas of the hematoxylin and eosin stained 10 µmthick sections of the formalinfixed, paraffin em bedded tissue. The genomic DNA was extracted using the ex traction buffer solution (50 mM Tris buffer, pH 8.3; 1 mM EDTA, pH 8.0; 5% Tween 20 and 100 µg/mL proteinase K). Mutations of V600E (T1799A) and K601E (A1801G) in exon 15 of the BRAF gene and the codons 12, 13, and 61 of the KRAS and NRAS genes were evaluated by the pyrosequencing meth od. The DNA extracted from the FVPTC foci revealed a BRAF K601E (A1801G) mutation. The conventional PTCs revealed BRAF V600E (T1799A) mutations in all 3 tumors (Fig. 3) . Neither the conventional nor follicular variant revealed KRAS or NRAS mutations.
DISCUSSION
The most characteristic growth pattern of PTC is papillary, although it is rarely pure and is typically mixed together with a variable proportion of neoplastic follicles. Papillary growth pre dominates in approximately two thirds of these tumors, where as another one third is predominantly follicular in characteriza tion. Other histological patterns include solid and trabecular patterns, which are observed in about 20% of cases, but are rare ly described as predominate. 12 The present case revealed three conventional PTCs and one FVPTC that were distinguished by a complete lack of wellformed papillae, an exclusively micro follicular growth pattern and the characteristic nuclear features of conventional PTC.
As a mPTC, this case was genetically very unique in that dif ferent kinds of BRAF mutations were found simultaneously in accordance with the different histological foci of mPTC. Three conventional PTCs of mPTC had the BRAF V600E (T1799A) mutation and the discrete, noncontiguous FVPTC exhibited the BRAF K601E (A1801G) mutation. To our knowledge, it has never been reported that two different BRAF mutations were noted together in the mPTC of an individual patient at the same time. In previous studies regarding mPTC and its ge netic alterations, some cases of mPTC revealed a discordant and mixed pattern of BRAF V600E mutation with a combination of BRAF V600Epositive BRAF V600Enegative PTC foci, al though most mPTC exhibited a concordant pattern of either all positive or negative with regards to its BRAF V600E mutation status. 5 Since PTC foci that do not harbor the BRAF V600E mutation often show different histopathological types other than the conventional type, BRAFdiscordant mPTC tend to show different morphotypes between tumor foci. 5 The present case corresponds to the small population of mPTC exhibiting the different morphotype and the discordance of BRAF V600E mutations among discrete tumor foci of mPTC. Moreover, our case was characterized by the presence of the BRAF K601E (A1801G) mutation in BRAF V600Enegative FVPTC foci. If we consider a very low incidence of 7% of BRAF K601E muta tions in solitary FVPTC, 4 this simultaneous presence of BRAF K601E and V600E mutations must be a very rare event with regards to genetic alterations observed in mPTC. In comparing the frequency of the BRAF K601E mutation with that of the BRAF V600E mutation in FVPTC, the BRAF V600E muta tion is more commonly detected in FVPTC due to its high prev alence in PTC. However, the BRAF K601E mutation has spe cial diagnostic value for the detection of FVPTC in that most of this mutation has been encountered and described in FVPTC, although it has been reported in a few cases of follicular adeno ma and carcinoma. 4, 13 The discordant pattern of BRAF mutations in the present case might be associated with the question whether mPTC arise de novo or from intrathyroidal metastasis. The observed discor dant pattern of BRAF mutations in our case seems to support the concept of de novo development of mPTC, suggesting an in dependent origin of the different tumor foci. However, because there was a previous study that reported that mPTC showing a discordant pattern of BRAF mutations usually has monoclonal derivation when considering the result of genomewide allelic imbalances, 5, 11 it remains uncertain whether our case resulted from de novo tumorigenesis or intraglandular spread.
Immunohistochemical staining showed focal weak positivity to CK19 and no reactivity to galectin 3 in FVPTC, in contrast to diffuse strong reactivity of both makers in conventional PTC. The difference of galectin 3 expression between the convention al type and the follicular variant has been suggested in the pre vious studies. A large scale comprehensive study reported that the incidence of galectin 3 expression in FVPTC (79.7%) was significantly lower than that of conventional PTC (98.3%), 14 although some previous studies on small numbers of FVPTC reported that galectin 3 was expressed in almost all cases like the conventional types. 15, 16 In terms of CK19 expression, there was no significant difference between FVPTC and the conven tional PTC in previous studies. 16, 17 However, the numbers of FVPTC cases analyzed in these studies on CK19 expression was too small to be generalized. Decreased expression of CK19 and galectin 3 in FVPTC of the present mPTC may reflect the imm nohistochemical features of the encapsulated variant of FVPTC. Whether the prognosis of mPTC is worse than that of soli tary PTC is controversial. Several previous studies have demon strated that mPTC was associated with a higher rate of recur rence, whereas Schindler et al. 18 suggested the opposite. 12 The present case consisted of three conventional PTC foci with BRAF V600E mutations and one encapsulated FVPTC foci with the BRAF K601E mutation. Considering that the behavior of en capsulated FVPTC was reported to be indolent in most cases, 19 the conventional PTC foci are more likely to affect the clinical course of this patient. In addition, the predominant role of con ventional PTC foci in reference to the prognosis might be asso ciated with the fact that BRAF V600E has about 2.5 times the kinase activity of BRAF K601E. 20 In summary, we report a genetically unique case of mPTC having the BRAF V600E (T1799A) mutation in conventional PTC foci and the BRAF K601E (A1801G) mutation in non contiguous, discrete follicular variant foci, simultaneously. Fig. 3 . The pyrosequencing analysis of the BRAF mutation shows the BRAF K601E (A1801G) mutation in one follicular variant (A) and the BRAF V600E (T1799A) mutation in three conventional types (B) of multifocal papillary thyroid carcinoma. (A) When the substitution of thymine to cytosine occurs at nucleotide 1801 of exon 15 in the reverse strand, an additional cytosine peak is fused to the next cytosine peak (arrowhead) at nucleotide 1800 with a decrease of the thymine peak at nucleotide 1801 in mutational analysis of the follicular variant. (B) In the three conventional types, the additional thymine peak (arrow) is shown with a decrease of the adenine peak at nucleotide 1799 in reading along the reverse strand. 
